Mairs & Power Inc Abb Vie Inc. Transaction History

Mairs & Power Inc

$10.5 Billion
Q3 2024

A detailed history of Mairs & Power Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Mairs & Power Inc holds 46,746 shares of ABBV stock, worth $8.21 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

46,746

Previous 46,351 0.85%

Holding current value

$8.21 Million

Previous $7.95 Million 16.11%

% of portfolio

0.09%

Previous 0.08%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$163.84 - $199.33 $64,716 - $78,735	395 Added 0.85%	46,746 $9.23 Million
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $420,874 - $491,486	2,719 Added 6.23%	46,351 $7.95 Million
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $583,662 - $665,029	-3,652 Reduced 7.72%	43,632 $7.95 Million
Q4 2023 Feb 14, 2024	SELL	$137.6 - $154.97 $96,044 - $108,169	-698 Reduced 1.45%	47,284 $7.33 Million
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $212,541 - $246,048	-1,591 Reduced 3.21%	47,982 $7.15 Million
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $442,318 - $550,436	-3,338 Reduced 6.31%	49,573 $6.68 Million
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $13,304 - $15,321	-92 Reduced 0.17%	52,911 $8.43 Million
Q4 2022 Feb 14, 2023	SELL	$138.31 - $165.87 $125,862 - $150,941	-910 Reduced 1.69%	53,003 $8.57 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $405,985 - $465,638	3,025 Added 5.94%	53,913 $7.24 Million
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $152,345 - $193,680	1,107 Added 2.22%	50,888 $7.79 Million
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $344,863 - $427,878	-2,613 Reduced 4.99%	49,781 $8.07 Million
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $184,349 - $233,255	1,716 Added 3.39%	52,394 $7.09 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $26,280 - $29,832	247 Added 0.49%	50,678 $5.47 Million
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $190,535 - $212,267	-1,811 Reduced 3.47%	50,431 $5.68 Million
Q1 2021 May 14, 2021	SELL	$102.3 - $112.62 $1.56 Million - $1.71 Million	-15,221 Reduced 22.56%	52,242 $5.65 Million
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $54,330 - $73,352	-675 Reduced 0.99%	67,463 $7.23 Million
Q3 2020 Nov 16, 2020	SELL	$85.91 - $100.83 $76,545 - $89,839	-891 Reduced 1.29%	68,138 $5.97 Million
Q2 2020 Aug 14, 2020	SELL	$73.37 - $98.18 $84,522 - $113,103	-1,152 Reduced 1.64%	69,029 $6.78 Million
Q1 2020 May 15, 2020	SELL	$64.5 - $97.79 $370,617 - $561,901	-5,746 Reduced 7.57%	70,181 $5.35 Million
Q4 2019 Feb 14, 2020	BUY	$72.13 - $90.25 $9,160 - $11,461	127 Added 0.17%	75,927 $6.72 Million
Q3 2019 Nov 14, 2019	SELL	$62.98 - $75.72 $203,047 - $244,121	-3,224 Reduced 4.08%	75,800 $5.74 Million
Q2 2019 Aug 14, 2019	SELL	$65.7 - $83.98 $366,080 - $467,936	-5,572 Reduced 6.59%	79,024 $5.75 Million
Q1 2019 May 15, 2019	SELL	$77.14 - $90.79 $1.12 Million - $1.32 Million	-14,545 Reduced 14.67%	84,596 $6.82 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $1.29 Million - $1.59 Million	-16,527 Reduced 14.29%	99,141 $9.14 Million
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $4.92 Million - $5.47 Million	-55,309 Reduced 32.35%	115,668 $10.9 Million
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $344,216 - $407,285	-3,834 Reduced 2.19%	170,977 $15.8 Million
Q1 2018 May 15, 2018	SELL	$92.01 - $123.21 $664,404 - $889,699	-7,221 Reduced 3.97%	174,811 $16.5 Million
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $1.44 Million - $1.58 Million	-16,093 Reduced 8.12%	182,032 $17.6 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $13.8 Million - $17.7 Million	198,125	198,125 $17.6 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mairs & Power Inc, based on Form 13F filings with the SEC.

News

Stay updated on Mairs & Power Inc with notifications on news.

Account